Personalized Ocular Pain Management System

A next-generation system for predicting, preventing, and treating ocular pain, leveraging advanced technologies such as wearable sensors, machine learning, and nanoparticle-based delivery systems to provide personalized and targeted relief.

The original patent relates to the use of prostacyclin antagonists for treating ocular surface nociception, but it has limitations in terms of efficacy, dosage, and patient variability. The new inventive concept addresses these limitations by integrating advanced technologies to provide a more comprehensive and personalized approach to ocular pain management.

The system comprises a wearable sensor that detects ocular surface nociception and transmits signals to a machine learning algorithm, which analyzes the data to predict and prevent ocular pain. The system also includes a prostacyclin antagonist dispenser that administers a therapeutically effective amount of the antagonist in response to the analysis. Additionally, the system may incorporate genetic analysis to determine a patient's genetic predisposition to ocular pain sensitivity, allowing for personalized dosage regimens. The composition may utilize nanoparticle-based delivery systems for targeted release of the antagonist to the ocular surface. The system may also include remote monitoring and management capabilities, utilizing mobile applications and cloud-based servers to track symptoms and provide personalized treatment recommendations.

The new inventive concept introduces the use of wearable sensors, machine learning algorithms, and nanoparticle-based delivery systems to provide personalized and targeted relief from ocular pain. The integration of these advanced technologies with prostacyclin antagonists represents a significant departure from the original patent and provides a novel solution to the limitations of existing treatments.

Alternative embodiments of the system may include the use of different types of sensors, such as electroencephalography (EEG) or functional near-infrared spectroscopy (fNIRS), to detect ocular surface nociception. The system may also be adapted for use in different ocular conditions, such as glaucoma or cataracts. Additionally, the system may be integrated with other therapies, such as neurostimulation devices, to provide a comprehensive approach to ocular pain management.

The personalized ocular pain management system has significant commercial potential in the pharmaceutical and medical device industries, particularly in the areas of ophthalmology and pain management. The system's ability to provide targeted and personalized relief from ocular pain addresses a significant unmet need in the market, and its integration of advanced technologies makes it an attractive solution for patients and healthcare providers.